Abstract Background and Objective Memantine, a frequently prescribed anti-dementia drug,
is mainly eliminated unchanged by the kidneys, partly via tubular secretion. Considerable …

Nongenetic biologic and lifestyle-related factors, including age, sex, hepatic/renal function,
diet/exercise practices, illness severity, smoking, and alcohol consumption habits can …

Background: Mood disorders represent a risk factor for dementia and are present in over
60% of cases with Alzheimer's disease (AD). More than 80% variability in drug …

Pharmacological treatment in Alzheimer's disease (AD) accounts for 10–20% of direct costs,
and fewer than 20% of AD patients are moderate responders to conventional drugs …

Abstract Neurodegenerative disorders (NDDs)(Alzheimer's disease, Parkinson's disease)
represent major problems of health in developed countries, with important psychosocial …

Adverse drug reactions, due at least in part to interindividual variability in drug response,
rank between the 4th and 6th leading causes of death in the USA. The field of …

For most drug-metabolizing enzymes (DMEs), the functional consequences of genetic
polymorphisms have been examined. Variants leading to reduced or increased enzymatic …

Introduction: Donepezil is a highly selective acetylcholinesterase inhibitor and one of the
only four drugs currently approved for treatment of Alzheimer's dementia. Providing high …

Background: Several randomized trials have demonstrated superiority of memantine-
cholinesterase inhibitor combination therapy in patients with moderate to severe Alzheimer's …

Background Alzheimer's disease (AD) is the most common neurodegenerative disease.
Studying the effects of drug treatments on multiple health outcomes related to AD could be …